Rupture of the interventricular septum (IVS) is considered one of the most dangerous and life-threatening complications of acute myocardial infarction (AMI). In the absence of surgical treatment, mortality is up to 70% in the first 3 days.

Due to the introduction of coronary revascularization (stenting) into everyday practice in AMI, the risk of postinfarction ventricular septal defects (VSD) gradually decreased: from 1–3% with drug treatment to 0.17–0.31% with a modern percutaneous stenting strategy.

The main method of treatment for postinfarction VSD is surgery, although it is still accompanied by a high risk of perioperative complications and mortality.

But the development of modern life support technologies has made it possible to change the treatment paradigm for this formidable complication. This became possible due to the introduction into clinical practice of endovascular closure of the ventricular septal defect (VSD). The use of a new generation of occlusive devices can significantly reduce operational risks in such extremely difficult clinical situations.